Management of Relapsed/Refractory Multiple Myeloma

Presented by:
Natalie S. Callander
Search for other papers by Natalie S. Callander in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

The treatment of relapsed multiple myeloma is based in part on the degree of previous exposure and resistance to commonly used drug classes. For patients with a first relapse, an anti-CD38 antibody–based combination is preferred unless patients have already received these agents, in which case a carfilzomib-based option can be an excellent choice. For patients with more refractory disease, a bispecific antibody is an emerging choice, but CAR T-cell therapy should also be considered for some patients; other options include salvage autologous transplantation, recycling of previous therapies, and selinexor-based therapies. Emerging new classes of drugs in development are poised to broaden the treatment possibilities for relapsed disease.

Disclosures: Dr. Callander has disclosed having no relevant financial relationships.

Correspondence: Natalie S. Callander, MD, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792. Email: nsc@medicine.wisc.edu
  • Collapse
  • Expand
  • 1.

    Hagen PA, Stiff P. The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma. Biol Blood Marrow Transplant 2019;25:e98107.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020;34:18751884.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754766.

  • 4.

    Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:801812.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol 2022;23:416427.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021;397:23612371.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379:18111822.

  • 8.

    Baljevic M, Gasparetto C, Schiller GJ, et al. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. EJHaem 2022;3:12701276.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022;387:495505.

  • 10.

    Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705716.

  • 11.

    Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023;41:12651274.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Hansen DK, Sidana S, Peres L, et al. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: real-world experience. Presented at the 2022 ASCO Annual Meeting; June 3–7, 2022; Chicago, Illinois. Abstract 8042.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388:10021014.

  • 14.

    Costa LJ, Kumar S, Atrash S, et al. Results from the first phase I clinical study of the B-cell maturation antigen NEX-T chimeric antigen receptor T cell therapy CC-98633/BMS-986354 in patients with relapsed/refractory multiple myeloma. Presented at the 64th ASH Annual Meeting and Exposition; December 10–13, 2022; New Orleans, Louisiana. Abstract 566.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Van Oekelen O, Nath K, Mouhieddine TH, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood 2023;141:756765.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381:727738.

  • 17.

    Lonial S, Nooka AK, Thulasi P, et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J 2021;11:103.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Jakubowiak AJ, Bahlis NJ, Raje NS, et al. Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: updated results from MagnetisMM-1. J Clin Oncol 2022;40(Suppl):Abstract 8014.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Raje N, Bahlis NJ, Costello C, et al. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Presented at the 64th ASH Annual Meeting and Exposition; December 10–13, 2022; New Orleans, Louisiana. Abstract 158.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Zonder JA, Richter J, Bumma N, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1/2 first-in- human study in patients with relapsed/refractory multiple myeloma. Blood 2021;138(Suppl 1):Abstract 160.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Bumma N, Richter J, Brayer J, et al. Updated safety and efficacy of REGN5458, a BCMAxCD3 bispecific antibody, treatment for relapsed/refractory multiple myeloma: a phase 1/2 first-in-human study. Presented at the 64th ASH Annual Meeting and Exposition; December 10–13, 2022; New Orleans, Louisiana. Abstract 4555.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    D’Souza A, Shah N, Rodriguez C, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol 2022;40:35763586.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Harrison JS, Minnema MC, Lee HC, et al. A phase 1 first in human study of AMG 701, an anti-B-cell maturation antigen half-life extended BiTE (bispecific T-cell engager) molecule, in relapsed/refractory multiple myeloma. Presented at the 62nd ASH Annual Meeting and Exposition; December 5–8, 2020. Abstract 181.

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1324 737 29
PDF Downloads 973 482 27
EPUB Downloads 0 0 0